* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insight Molecular Diagnostics Effective Interest Rate on Debt % Chart
IMDX vs XGN, BDSX, BNR: Effective Interest Rate on Debt % Comparison
For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insight Molecular Diagnostics Effective Interest Rate on Debt % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Effective Interest Rate on Debt % distribution charts can be found below:
* The bar in red indicates where Insight Molecular Diagnostics's Effective Interest Rate on Debt % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data,
the Interest Expense data used here is four times the quarterly (Mar. 2026) interest expense data.
Effective Interest Rate on Debt % is displayed in the 30-year financial page.
What does a Effective Interest Rate on Debt % of 2.80% mean?
Insight Molecular Diagnostics (IMDX) has a Effective Interest Rate on Debt % of 2.80% as of Mar. 2026. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Insight Molecular Diagnostics and its competitors.
Is Insight Molecular Diagnostics' Effective Interest Rate on Debt % too high?
Insight Molecular Diagnostics' current Effective Interest Rate on Debt % is 2.80%. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' Effective Interest Rate on Debt % compare to XGN and BDSX?
Insight Molecular Diagnostics' Effective Interest Rate on Debt % of 2.80% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Medical Diagnostics & Research company?
A good Effective Interest Rate on Debt % depends on the Medical Diagnostics & Research industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Insight Molecular Diagnostics and its competitors. Insight Molecular Diagnostics's current Effective Interest Rate on Debt % is 2.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.25, compared to a current price of $5.74 — trading 359.2% above its estimated fair value. The current Effective Interest Rate on Debt % is 2.80%. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current Effective Interest Rate on Debt % is 2.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?
Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued.
The current stock price of $5.74 is trading 359.2% above its estimated GF Value™ of $1.25.
GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.
Key valuation signals for IMDX:
Effective Interest Rate on Debt %: 2.80%
GF Value™: $1.25 vs. price of $5.74 (359.2% above fair value)
No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insight Molecular Diagnostics Business Description
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score
Get the complete analysis for IMDX
Effective Interest Rate on Debt % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMDX has been successfully added to your 
